Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $350 from $348 and keeps a Buy rating on the shares. The firm, which is updating its model to reflect Q1 results, maintains its “positive conviction” on what it identifies as its top Midcap Biotech stock pick.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.